Immunovant Raises $550 Million to Support IMVT-1402 Launch for Graves' Disease
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: Globenewswire
- Funding Size: Immunovant announced an underwritten offering of 26.2 million shares at $21.00 per share, anticipating gross proceeds of approximately $550 million, which will be utilized to support the potential launch of IMVT-1402 for Graves' disease.
- Shareholder Participation: Controlling shareholder Roivant Sciences Ltd. has agreed to purchase shares in the offering, reflecting confidence in the company's future and enhancing market support for Immunovant.
- Use of Proceeds: The funds raised will be combined with existing cash and cash equivalents, expected to sufficiently cover operating expenses and capital expenditures, ensuring financial stability leading up to the IMVT-1402 launch.
- Market Outlook: The successful launch of IMVT-1402 could open new revenue streams for Immunovant, further solidifying its market position in the autoimmune disease sector and driving long-term growth for the company.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like IMVT with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on IMVT
Wall Street analysts forecast IMVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMVT is 37.00 USD with a low forecast of 22.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 26.060
Low
22.00
Averages
37.00
High
54.00
Current: 26.060
Low
22.00
Averages
37.00
High
54.00
About IMVT
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Purcell & Lefkowitz Investigates Immunovant's Board Actions for Shareholder Breach
- Investigation Launched: Purcell & Lefkowitz LLP is investigating Immunovant, Inc.'s board to determine if they breached fiduciary duties in recent corporate actions, potentially impacting shareholder rights.
- Shareholder Rights Protection: The investigation focuses on safeguarding Immunovant shareholders' interests, and shareholders seeking more information can contact the law firm via their website or phone to ensure their voices are heard.
- Legal Support: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide against securities fraud and other corporate misconduct, demonstrating a strong commitment to protecting shareholder rights.
- Potential Impact: Should the investigation confirm misconduct by the board, it could lead to legal liabilities for the company, thereby affecting shareholder investment value and market trust.
Continue Reading
IMVT Options Trading Kicks Off in February 2026
Put Contract Overview: The $23.00 put contract has a bid of 70 cents, allowing investors to buy IMVT shares at a cost basis of $22.30, which is a 14% discount from the current price of $26.59. There is a 75% chance the contract may expire worthless, offering a potential 3.04% return on cash commitment.
Call Contract Overview: The $29.00 call contract has a bid of $1.20, enabling investors to sell IMVT shares at that price after purchasing them at $26.59. This could yield a 13.58% return if the stock is called away, with a 56% chance of the contract expiring worthless, resulting in a 4.51% additional return.
Volatility Insights: The implied volatility for the put contract is 70%, while for the call contract it is 64%. The actual trailing twelve-month volatility is calculated at 57%, based on the last 250 trading days.
YieldBoost Concept: Both the put and call contracts offer potential YieldBoosts, with the put providing a 17.63% annualized return if it expires worthless, and the call offering a 26.15% annualized return under similar conditions.
Continue Reading